IL2 and chronic myelogenous leukemia, BCR-ABL1 positive: However, in a clinical study of Dasatinib on chronic myelocytic leukemia (CML), patients taking Dasatinib had significantly reduced plasma IL-2 levels, suppressed STAT5 phosphorylation in Tregs cells, and TIM-3-mediated exhaustion of CD8+ T cells (122).